TY - JOUR
T1 - Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis
T2 - Physical and pharmacological properties underlie the observed clinical efficacy and safety
AU - Kolbinger, Frank
AU - Di Padova, Franco
AU - Deodhar, Atul
AU - Hawkes, Jason E.
AU - Huppertz, Christine
AU - Kuiper, Torsten
AU - McInnes, Iain B.
AU - Ritchlin, Christopher T.
AU - Rosmarin, David
AU - Schett, Georg
AU - Carballido, José M.
AU - Häusermann, Peter
AU - Calonder, Claudio
AU - Vogel, Beate
AU - Rondeau, Jean Michel
AU - Bruin, Gerard
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2022/1
Y1 - 2022/1
N2 - Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases, each commonly manifesting as a spectrum of symptoms, complications, and comorbidities that arise differently in individual patients. Drugs targeting inflammatory cytokines common to the pathogenesis of each of these conditions have been developed, although their specific actions in the different tissues involved are variable. For a drug to be effective, it must be efficiently delivered to and locally bioactive in disease-relevant tissues. Detailed clinical data shed light on the therapeutic effects of individual biologics on specific domains or clinical manifestations of disease and assist in guiding treatment decisions. Pharmacologic, molecular, and functional properties of drugs strongly impact their observed safety and efficacy, and an understanding of these properties provides complementary insight. Secukinumab, a fully human monoclonal IgG1/κ antibody selectively targeting interleukin (IL)-17A, has been in clinical use for >6 years in the treatment of moderate to severe psoriasis, psoriatic arthritis, and both radiographic (also known as ankylosing spondylitis) and nonradiographic axial spondyloarthritis. In this review, we discuss pharmacokinetic and pharmacodynamic data for secukinumab to introduce clinicians to the pharmacological properties of this widely used drug. Understanding how these properties affect the observed clinical efficacy, safety, and tolerability of this drug in the treatment of IL-17A–mediated systemic inflammatory diseases is important for all physicians treating these conditions.
AB - Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases, each commonly manifesting as a spectrum of symptoms, complications, and comorbidities that arise differently in individual patients. Drugs targeting inflammatory cytokines common to the pathogenesis of each of these conditions have been developed, although their specific actions in the different tissues involved are variable. For a drug to be effective, it must be efficiently delivered to and locally bioactive in disease-relevant tissues. Detailed clinical data shed light on the therapeutic effects of individual biologics on specific domains or clinical manifestations of disease and assist in guiding treatment decisions. Pharmacologic, molecular, and functional properties of drugs strongly impact their observed safety and efficacy, and an understanding of these properties provides complementary insight. Secukinumab, a fully human monoclonal IgG1/κ antibody selectively targeting interleukin (IL)-17A, has been in clinical use for >6 years in the treatment of moderate to severe psoriasis, psoriatic arthritis, and both radiographic (also known as ankylosing spondylitis) and nonradiographic axial spondyloarthritis. In this review, we discuss pharmacokinetic and pharmacodynamic data for secukinumab to introduce clinicians to the pharmacological properties of this widely used drug. Understanding how these properties affect the observed clinical efficacy, safety, and tolerability of this drug in the treatment of IL-17A–mediated systemic inflammatory diseases is important for all physicians treating these conditions.
KW - Axial spondyloarthritis
KW - Biologics
KW - IL-17
KW - Psoriasis
KW - Psoriatic arthritis
KW - Secukinumab
UR - http://www.scopus.com/inward/record.url?scp=85110550400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110550400&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2021.107925
DO - 10.1016/j.pharmthera.2021.107925
M3 - Review article
C2 - 34171337
AN - SCOPUS:85110550400
SN - 0163-7258
VL - 229
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
M1 - 107925
ER -